Randomized Controlled Study of Kuanxiong Aerosol in the Treatment of Cardiac Insufficiency After Percutaneous Coronary Intervention in Coronary Atherosclerotic Heart Disease
Objective To explore the clinical efficacy of Kuanxiong Aerosol in the treatment of coronary heart disease(CHD)patients with cardiac insufficiency after percutaneous coronary intervention(PCI).Methods A total of 172 CHD patients with cardiac dysfunction after PCI were randomly assigned to trial group and control group,with 86 cases in each group.Both groups received guideline-directed medical therapy treatment,and the trial group received Kuanxiong Aerosol treatment,the course was 1 month.Clinical efficacy and Chinese medicine syndrome score before and after treatment were evaluated.Cardiac function index including left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),6-minute walk test(6MWT),serum N-terminal pro-brain natriuretic peptide(NT-proBNP)were detected.The quality of life was assessed by Seattle Angina Questionnaire(SAQ).Results All patients completed the study.Compared with baseline,the Chinese medicine syndrome score and serum NT-proBNP decreased,and 6MWT,LVEF and each dimension of SAQ increased after treatment in both groups(P＜0.05).Compared with the control group in the same period,the Chinese medicine syndrome score and serum NT-proBNP decreased,and 6MWT,LVEF,SAQ angina pectoris stable state,angina pectoris attack frequency and treatment satisfaction increased in the trial group after treatment(P＜0.05).Compared with control group,the efficacy of the trial group increased(P＜0.01)Conclusions Kuanxiong Aerosol can improve the cardiac function,Chinese medicine syndrome score and quality of life of CHD patients with cardiac insufficiency after PCI.(ClinicalTrials.gov,No.NCT06480097)
国家科技期刊平台
NSTL
万方数据
